A Phase 3 interventional study of Ensifentrine and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma plc. Completed at 122 sites in 12 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 7th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 763 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 18th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Capable of giving informed consent indicating that they understand the purpose of the study and study procedures and agree to comply with the requirements and restrictions listed in the informed consent form (ICF).
Age and Sex
Sex:
Females are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions apply:
Smoking History
Smoking History: Current or former cigarette smokers with a history of cigarette smoking ≥10 pack years at Screening (Visit 0) [number of pack years = (number of cigarettes per day / 20) × number of years smoked (eg, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 0. Smoking cessation programs are permitted during the study.
Diagnosis, Symptoms, Severity and Maintenance Therapy
COPD Severity:
Maintenance Therapy: Patients on no maintenance/background therapy or patients on stable maintenance LAMA or LABA therapy are eligible. Patients taking maintenance LAMA or LABA therapy must demonstrate stable use of the maintenance LAMA or LABA therapy for at least 3 months prior to Screening and agree to continue use for the duration of the study. Background maintenance LAMA or LABA bronchodilator therapy will be capped at 50% of patients.
Other Requirements for Inclusion
Inclusion Criteria at Randomization (RPL554-CO-301)
Exclusion Criteria:
Current Condition or Medical History
Historical or current evidence of clinically significant cardiovascular disease defined as any disease that in the opinion of the Investigator would put the safety of the patient at risk through participation or which could affect the efficacy or safety analysis if the disease/condition were to exacerbate during the study, including, but not limited to:
Findings on physical examination that an investigator considers to be clinically significant at Screening.
Prior/Concomitant Therapy
Use of prohibited medications within the time intervals.
History or Suspicion of Drug or Alcohol Abuse
Current or history of past drug or alcohol abuse within the past 5 years.
Laboratory and Other Diagnostic Parameters
(ECG) finding that is significantly abnormal on the 12-lead ECG obtained at Screening.
Other Exclusions
Exclusion Criteria at Randomization (RPL554-CO-301)
Significantly abnormal ECG finding on the 12-lead ECG obtained at Screening as assessed by the investigator or site medical doctor/medically qualified person or on the pre-dose (prior to randomization) ECG obtained at Visit 1.
In the event that the central ECG reviewer discovers a significant ECG abnormality on the Visit 1 ECG, the patient will be discontinued.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ensifentrine Nebulized Suspension; 3 mg BID
Drug: Ensifentrine
Placebo Nebulized BID
Drug: Placebo
Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-12h was defined as AUC over 12 hours of the FEV1, divided by 12 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.
Time frame: Baseline (pre-dose on Day 1) and Week 12
LS Mean Change From Baseline FEV1 to Peak FEV1 at Day 1 and Weeks 6, 12 and 24
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Peak FEV1 is the maximum value in the 4 hours after dosing. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (pre-dose on Day 1), post-dose on Day 1, Weeks 6, 12, and 24
LS Mean Change From Baseline to the Mean Weekly Evaluating-Respiratory Symptoms (E-RS) Total Score at Weeks 6, 12 and 24
The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS total score was derived as the sum of the raw scores of the 11 items ranging from 0 to 40. Higher scores indicates severe respiratory symptoms. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS was collected daily by electronic diary (e-diary). Baseline is the mean over the 7 days prior to the first intake of study medication, using only days where data was recorded.
Time frame: Baseline (pre-dose on Day 1) and Weeks 6, 12, and 24
LS Mean Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 6, 12 and 24
The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Score ranging from 0 to 100 and higher scores indicated a worse outcome. Baseline is the score calculated on Day 1 prior to 4 hour post-dose spirometry.
Time frame: Baseline (pre-dose on Day 1) and Weeks 6, 12, and 24
LS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 6, 12 and 24
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Morning trough FEV1 was the last value collected prior to the morning dose. Baseline FEV1 is the mean of the two measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (pre-dose on Day 1) and Weeks 6, 12, and 24
LS Mean Change From Baseline in Average FEV1 Area Under the Curve Over 4 Hours (AUC0-4h) at Day 1 and Weeks 6, 12 and 24
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-4h was defined as area under the curve over 4 hours of the FEV1, divided by 4 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (pre-dose on Day 1), post-dose on Day 1, Weeks 6, 12, and 24
Percentage of SGRQ Responders at Weeks 6, 12 and 24
The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Responder was a patient with an improvement from baseline in SGRQ total score of 4 or more. Percentage of SGRQ responders are reported.
Time frame: Weeks 6, 12 and 24
LS Mean Change From Baseline to the Mean Weekly Rescue Medication Use at Weeks 6, 12 and 24
Use of rescue medication (albuterol/salbutamol) per week was calculated as the LS mean use daily over 7 days. Daily rescue medication use was collected in an e-diary throughout the study. Baseline is the mean over the 7 days prior to the first intake of study medication, calculated as the sum of puffs taken, divided by number of days data has been recorded.
Time frame: Baseline (pre-dose on Day 1) and Weeks 6, 12, and 24
LS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 6, 12 and 24
The TDI is a questionnaire that focused on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome. Change from baseline was assessed with the Baseline Dyspnea Index.
Time frame: Weeks 6, 12 and 24
LS Mean Change From Baseline FEV1 to Evening Trough FEV1 at Week 12
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Evening trough FEV1 was the value collected at 12 hours post-morning dose and prior to the evening dose. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (pre-dose on Day 1) and Week 12
This Phase 3, randomized, double-blind, placebo-controlled study was conducted in patients with moderate to severe chronic obstructive pulmonary disease (COPD) at 120 study centers in 12 countries between 29 Sep 2020 and 02 Dec 2022. Patients were randomized in a 5:3 ratio overall (1:1 over 24 weeks and 3:1 over 48 weeks), stratified by duration, smoking status and background medication use, to receive either ensifentrine or placebo.
| Milestone | Ensifentrine | Placebo |
|---|---|---|
| Started | 479 | 284 |
| Received treatment | 477 | 283 |
| Completed | 400 | 245 |
| Not completed | 79 | 39 |
| Withdrew: Death | 4 | 5 |
| Withdrew: Copd exacerbation withdrawal criteria | 7 | 5 |
| Withdrew: Coronavirus disease 2019 (covid-19) | 8 | 6 |
| Withdrew: Adverse event | 10 | 1 |
| Withdrew: Lack of efficacy | 3 | 2 |
| Withdrew: Investigator discretion | 3 | 0 |
| Withdrew: Withdrawal by subject | 32 | 14 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Other | 7 | 3 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-12h was defined as AUC over 12 hours of the FEV1, divided by 12 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.
| liters | Ensifentrine | Placebo |
|---|---|---|
| Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 | 0.0611 ± 0.01825 | -0.0256 ± 0.0195 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Peak FEV1 is the maximum value in the 4 hours after dosing. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | Ensifentrine | Placebo |
|---|---|---|
| Day 1 (Post-dose) | 0.2274 ± 0.0130 | 0.0755 ± 0.0138 |
| Week 6 | 0.2038 ± 0.0193 | 0.0677 ± 0.0207 |
| Week 12 | 0.2042 ± 0.0201 | 0.0570 ± 0.0217 |
| Week 24 | 0.1623 ± 0.0217 | 0.0462 ± 0.0234 |
The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS total score was derived as the sum of the raw scores of the 11 items ranging from 0 to 40. Higher scores indicates severe respiratory symptoms. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS was collected daily by electronic diary (e-diary). Baseline is the mean over the 7 days prior to the first intake of study medication, using only days where data was recorded.
| units on a scale | Ensifentrine | Placebo |
|---|---|---|
| Week 6 | -1.944 ± 0.3581 | -1.157 ± 0.3831 |
| Week 12 | -2.498 ± 0.3897 | -1.127 ± 0.4176 |
| Week 24 | -2.249 ± 0.4247 | -1.298 ± 0.4573 |
The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Score ranging from 0 to 100 and higher scores indicated a worse outcome. Baseline is the score calculated on Day 1 prior to 4 hour post-dose spirometry.
| units on a scale | Ensifentrine | Placebo |
|---|---|---|
| Week 6 | -6.184 ± 0.9838 | -3.965 ± 1.0511 |
| Week 12 | -5.665 ± 1.0163 | -2.652 ± 1.0859 |
| Week 24 | -6.167 ± 1.1405 | -3.868 ± 1.2178 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Morning trough FEV1 was the last value collected prior to the morning dose. Baseline FEV1 is the mean of the two measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | Ensifentrine | Placebo |
|---|---|---|
| Week 6 | 0.0112 ± 0.0181 | -0.0259 ± 0.0193 |
| Week 12 | 0.0076 ± 0.0190 | -0.0272 ± 0.0204 |
| Week 24 | -0.0236 ± 0.0205 | -0.0369 ± 0.0219 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-4h was defined as area under the curve over 4 hours of the FEV1, divided by 4 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | Ensifentrine | Placebo |
|---|---|---|
| Day 1 (Post-dose) | 0.1495 ± 0.0108 | 0.0099 ± 0.0115 |
| Week 6 | 0.1259 ± 0.0184 | -0.0044 ± 0.0196 |
| Week 12 | 0.1243 ± 0.0191 | -0.0149 ± 0.0203 |
| Week 24 | 0.0875 ± 0.0206 | -0.0139 ± 0.0220 |
The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Responder was a patient with an improvement from baseline in SGRQ total score of 4 or more. Percentage of SGRQ responders are reported.
| percentage of patients | Ensifentrine | Placebo |
|---|---|---|
| Week 6 | 50.8 | 40.6 |
| Week 12 | 52.5 | 37.0 |
| Week 24 | 58.2 | 45.9 |
Use of rescue medication (albuterol/salbutamol) per week was calculated as the LS mean use daily over 7 days. Daily rescue medication use was collected in an e-diary throughout the study. Baseline is the mean over the 7 days prior to the first intake of study medication, calculated as the sum of puffs taken, divided by number of days data has been recorded.
| rescue medication puffs per week | Ensifentrine | Placebo |
|---|---|---|
| Week 6 | -0.442 ± 0.1065 | -0.306 ± 0.1139 |
| Week 12 | -0.469 ± 0.1155 | -0.182 ± 0.1234 |
| Week 24 | -0.506 ± 0.1448 | -0.052 ± 0.1554 |
The TDI is a questionnaire that focused on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome. Change from baseline was assessed with the Baseline Dyspnea Index.
| units on a scale | Ensifentrine | Placebo |
|---|---|---|
| Week 6 | 1.3 ± 0.19 | 0.6 ± 0.21 |
| Week 12 | 1.6 ± 0.21 | 0.4 ± 0.23 |
| Week 24 | 1.9 ± 0.24 | 0.8 ± 0.27 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Evening trough FEV1 was the value collected at 12 hours post-morning dose and prior to the evening dose. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | Ensifentrine | Placebo |
|---|---|---|
| LS Mean Change From Baseline FEV1 to Evening Trough FEV1 at Week 12 | -0.0117 ± 0.0203 | -0.0697 ± 0.0214 |
Collected over Treatment-emergent adverse events (TEAEs; serious or non-serious), were collected from first dose of study medication up to 10 days after final study visit (24-week subset: at Week 24, approximately 25 weeks; 48-week subset: at Week 48, approximately 49 weeks). Serious Adverse Events (SAEs) assessed as related to study participation (eg, change in existing therapy) and which occurred prior to first dose of study medication were collected from time of consent through follow-up contact.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Up to Week 24: Ensifentrine | 2/477 (0.4%) | 32/477 (6.7%) | 90/477 (18.9%) |
| Up to Week 24: Placebo | 4/283 (1.4%) | 19/283 (6.7%) | 58/283 (20.5%) |
| From Week 24 to Week 48: Ensifentrine | 2/228 (0.9%) | 11/228 (4.8%) | 16/228 (7%) |
| From Week 24 to Week 48: Placebo | 1/70 (1.4%) | 5/70 (7.1%) | 17/70 (24.3%) |
| Event | Up to Week 24: Ensifentrine | Up to Week 24: Placebo | From Week 24 to Week 48: Ensifentrine | From Week 24 to Week 48: Placebo |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/477 | 6/283 | 2/228 | 0/70 |
| AnaemiaBlood and lymphatic system disorders | 0/477 | 1/283 | 0/228 | 1/70 |
| Vestibular disorderEar and labyrinth disorders | 0/477 | 0/283 | 0/228 | 1/70 |
| Pancreatitis acuteGastrointestinal disorders | 0/477 | 0/283 | 0/228 | 1/70 |
| Bile duct stoneHepatobiliary disorders | 1/477 | 0/283 | 0/228 | 1/70 |
| Lung abscessInfections and infestations | 0/477 | 0/283 | 0/228 | 1/70 |
| SepsisInfections and infestations | 1/477 | 0/283 | 0/228 | 1/70 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/477 | 0/283 | 0/228 | 1/70 |
| COVID-19Infections and infestations | 2/477 | 2/283 | 1/228 | 0/70 |
| COVID-19 pneumoniaInfections and infestations | 3/477 | 1/283 | 1/228 | 0/70 |
| Event | Up to Week 24: Ensifentrine | Up to Week 24: Placebo | From Week 24 to Week 48: Ensifentrine | From Week 24 to Week 48: Placebo |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 13/477 | 16/283 | 6/228 | 0/70 |
| HeadacheNervous system disorders | 16/477 | 12/283 | 4/228 | 2/70 |
| COVID-19Infections and infestations | 16/477 | 9/283 | 2/228 | 2/70 |
| HypertensionVascular disorders | 11/477 | 4/283 | 0/228 | 0/70 |
| Back painMusculoskeletal and connective tissue disorders | 10/477 | 1/283 | 0/228 | 0/70 |
| Upper respiratory tract infectionInfections and infestations | 6/477 | 5/283 | 4/228 | 0/70 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/477 | 0/283 | 0/228 | 1/70 |
| Supraventricular extrasystolesCardiac disorders | 0/477 | 0/283 | 0/228 | 1/70 |
| Food poisoningGastrointestinal disorders | 0/477 | 0/283 | 0/228 | 1/70 |
| AstheniaGeneral disorders | 0/477 | 0/283 | 1/228 | 1/70 |
All patients randomized set included all patients in the enrolled set who were randomized to study medication.
| Age, Continuous(years) | Ensifentrine | Placebo | Total |
|---|---|---|---|
| Mean | 65.1 ± 7.12 | 64.9 ± 7.73 | 65.0 ± 7.35 |
| Sex: Female, Male(Participants) | Ensifentrine | Placebo | Total |
|---|---|---|---|
| Female | 204 | 117 | 321 |
| Male | 275 | 167 | 442 |
| Race/Ethnicity, Customized(Participants) | Ensifentrine | Placebo | Total |
|---|---|---|---|
| Asian | 13 | 11 | 24 |
| Black or African American | 16 | 9 | 25 |
| White | 437 | 251 | 688 |
| Other | 0 | 1 | 1 |
| Not Reported | 13 | 12 | 25 |
| Race/Ethnicity, Customized(Participants) | Ensifentrine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 6 | 21 |
| Not Hispanic or Latino | 464 | 278 | 742 |
| Region of Enrollment(Participants) | Ensifentrine | Placebo | Total |
|---|---|---|---|
| Bulgaria | 28 | 17 | 45 |
| Czechia | 70 | 36 | 106 |
| Germany | 117 | 73 | 190 |
| Greece | 3 | 3 | 6 |
| Hungary | 25 | 14 | 39 |
| South Korea | 12 | 11 | 23 |
| Poland | 10 | 3 | 13 |
| Romania | 21 | 18 | 39 |
| Russia | 71 | 33 | 104 |
| Slovakia | 27 | 14 | 41 |
| United Kingdom | 8 | 4 | 12 |
| United States | 87 | 58 | 145 |
Showing the first 100 of 122 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Sep 2022, 23 months.
Results were first posted in Nov 2023, 1 year 2 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 23 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensifentrine
Pulmonary Disease, Chronic Obstructive →